Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

RASopathic skin eruptions during vemurafenib therapy.

Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, Dummer R, Belloni B.

PLoS One. 2013;8(3):e58721. doi: 10.1371/journal.pone.0058721. Epub 2013 Mar 14.

2.

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C.

Ann Oncol. 2013 Jun;24(6):1691-7. doi: 10.1093/annonc/mdt015. Epub 2013 Feb 13.

3.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Sibaud V, Lamant L, Maisongrosse V, Delord JP.

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19. Review. French.

PMID:
24034635
4.

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK.

Oncologist. 2013;18(3):314-22. doi: 10.1634/theoncologist.2012-0333. Epub 2013 Mar 1.

5.

A case of vemurafenib-induced keratosis pilaris-like eruption.

Wang CM, Fleming KF, Hsu S.

Dermatol Online J. 2012 Apr 15;18(4):7.

6.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
7.

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2012 Nov;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x. Epub 2012 Oct 5.

PMID:
22804352
8.

Cutaneous effects of BRAF inhibitor therapy: a case series.

Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.

Ann Oncol. 2013 Feb;24(2):530-7. doi: 10.1093/annonc/mds292. Epub 2012 Oct 3.

9.

Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.

Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, Coto-Segura P, Vazquez-Lopez F, Perez-Oliva N.

Dermatol Online J. 2013 Apr 15;19(4):16. Review.

10.

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F.

Eur J Cancer. 2013 May;49(7):1654-61. doi: 10.1016/j.ejca.2013.01.015. Epub 2013 Mar 5.

PMID:
23481513
11.

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Huang V, Hepper D, Anadkat M, Cornelius L.

Arch Dermatol. 2012 May;148(5):628-33. doi: 10.1001/archdermatol.2012.125.

PMID:
22431713
12.

Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy.

Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA.

Am J Dermatopathol. 2014 Jul;36(7):557-61. doi: 10.1097/DAD.0000000000000018.

PMID:
24950418
13.

Vemurafenib: an unusual UVA-induced photosensitivity.

Gelot P, Dutartre H, Khammari A, Boisrobert A, Schmitt C, Deybach JC, Nguyen JM, Seité S, Dréno B.

Exp Dermatol. 2013 Apr;22(4):297-8. doi: 10.1111/exd.12119.

PMID:
23528218
14.

Vemurafenib-associated keratoses with genetic heterogeneity of RAS.

Loh E, Hosler GA.

J Drugs Dermatol. 2014 Apr;13(4):495-7.

PMID:
24719071
15.

Cutaneous adverse events during vemurafenib therapy.

Chandrakumar SF, Yeung J.

J Cutan Med Surg. 2014 Jul-Aug;18(4):223-8. Review.

PMID:
25008438
16.

Vemurafenib. Value unclear in metastatic melanoma.

[No authors listed]

Prescrire Int. 2012 Dec;21(133):288-90.

PMID:
23373092
17.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.

J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

18.

Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.

Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC.

J Am Acad Dermatol. 2012 Dec;67(6):1375-9. doi: 10.1016/j.jaad.2012.06.045. Epub 2012 Aug 30. Review.

PMID:
22940405
19.

Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.

Brugière C, Stefan A, Morice C, Cornet E, Moreau A, Allouche S, Verneuil L.

Br J Dermatol. 2014 Dec;171(6):1529-32. doi: 10.1111/bjd.13300. Epub 2014 Nov 9.

PMID:
25066094
20.

[Successful drug desensitization after vemurafenib-induced rash].

Klossowski N, Kislat A, Homey B, Gerber PA, Meller S.

Hautarzt. 2015 Apr;66(4):221-3. doi: 10.1007/s00105-015-3590-4. German.

PMID:
25698338
Items per page

Supplemental Content

Write to the Help Desk